glp 1 agonist crohn's disease The role of GLP-1 RA in inflammatory bowel disease. The GLP-1 RA GLP-1 and GLP-2 Orchestrate Intestine

A systematic translational roadmap will be required to realize their potential in NDDs

More than one in ten people in Saudi Arabia is living with diabetes, and the prevalence of the disease will almost double by 2045, according to a report by the International Diabetes Federation

The magnitude of weight loss varies by product: semaglutide 2.4mg (Wegovy) can achieve approximately 15% reduction in body weight, while liraglutide 3mg (Saxenda) typically produces around 8% weight loss

Maintaining gradual rather than precipitous weight loss, ensuring adequate hydration, and avoiding prolonged fasting may help, but these approaches have not been specifically validated in patients taking these medications